In the Claims:

Please amend the claims as follows:

Cancel claims 7-8, 10 and 23-30 and amend the remaining claims as follows:

1. (Previously presented) A compound according to the structure:



where X is N_3, $NHCH_3$, $N(CH_3)_2$ or an aminocyclopropyl group;
R^1 is H or a C_1 to C_{20} acyl or alkyl group, a phosphate, diphosphate, triphosphate or phosphodiester group; and
R^2 is H or a C_1 to C_{20} acyl or alkyl group
or a pharmaceutically acceptable salt thereof.

2. (Original) The compound according to claim 1 wherein X is an aminocyclopropyl group.

3. (Previously presented) A pharmaceutical composition comprising an anti-HIV effective compound according to the structure:



where X is OCH_3, N_3, $NHCH_3$, $N(CH_3)_2$ or an aminocyclopropyl group;
R^1 is H or a C_1 to C_{20} acyl or alkyl group, a phosphate, diphosphate, triphosphate or phosphodiester group; and
R^2 is H or a C_1 (acetyl) to C_{20} acyl or alkyl group
or a pharmaceutically acceptable salt thereof, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

4. (Original) The composition according to claim 4 wherein X is an aminocyclopropyl group and R^1 and R^2 are H.

5. (Previously presented) A method for inhibiting the growth, elaboration and/or the replication of HIV in a patient comprising administering to said patient an anti-HIV effective amount of a compound according to the structure:



where X is OCH_3, N_3, $NHCH_3$, $N(CH_3)_2$ or an aminocyclopropyl group;
R^1 is H or a C_1 to C_{20} acyl or alkyl group, a phosphate, diphosphate, triphosphate or

phosphodiester group; and

R^2 is H or a C_1 to C_{20} acyl or alkyl group or a pharmaceutically acceptable salt thereof, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

6. (Original) The method according to claim 5 wherein X is an aminocyclopropyl group and R^1 and R^2 are H.

7-8. Cancelled.

9. (Previously presented) A pharmaceutical composition comprising a combination of an effective amount of a compound according to the structure:



where X is OCH_3, N_3, $NHCH_3$, $N(CH_3)_2$ or an aminocyclopropyl group;

R^1 is H or a C_1 to C_{20} acyl or alkyl group, a phosphate, diphosphate, triphosphate or phosphodiester group; and

R^2 is H or a C_1 to C_{20} acyl or alkyl group or a pharmaceutically acceptable salt thereof; and at least one additional agent selected from the group consisting of a nucleoside reverse transcriptase inhibitor, a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor, a HIV zinc finger inhibitor, a cell cycle inhibitor, a cytotoxic agent, an HIV integrase inhibitor, a nucleocapsid inhibitor, and a viral entry inhibitor, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

10. (Currently amended) The composition according to claim ~~7~~ 9 wherein X is an

aminocyclopropyl group and R^1 and R^2 are H.

11. (Original) The composition of claim 9 wherein said additional agent is a nucleoside reverse transcriptase inhibitor selected from the group consisting of AZT, 3TC, ddC, FTC, D4FC, D4T, ddI, PMPA, Bis(POC)PMPA and mixtures thereof.

12. (Currently amended) The composition of claim 9 wherein said additional agent is a non-nucleoside reverse transcriptase inhibitor selected from the group consisting of Nevirapine, Delavirdine, Efavirenz, Emivirine, TIBO, ~~GW420 867X~~ GW420867X, UC 781 and mixtures thereof.

13. (Currently amended) The composition of claim 9 wherein said additional agent is a protease inhibitor selected from the group consisting of Saquinavir, Amprenavir, Indinavir, Nelfinavir, Ritonavir, Tipranavir, ~~lopinavir~~ Lopinavir, GW433 908, Lasinavir and mixtures thereof.

14. (Original) The composition of claim 9 wherein said additional agent is selected from the group consisting of 1,1'-azobisformamide, hydroxyurea, LiGLA, and mixtures thereof.

15. (Previously presented) A method for inhibiting the growth, elaboration and/or the replication of HIV in a patient comprising administering to said patient a combination of an anti-HIV effective amount of a compound according to the structure:



where X is OCH_3, N_3, $NHCH_3$, $N(CH_3)_2$ or an aminocyclopropyl group;
R^1 is H or a C_1 to C_{20} acyl or alkyl group, a phosphate, diphosphate, triphosphate or phosphodiester group; and
R^2 is H or a C_1 to C_{20} acyl or alkyl group or a pharmaceutically acceptable salt thereof; and
at least one additional agent selected from the group consisting of a nucleoside reverse transcriptase inhibitor, a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor, a HIV zinc finger inhibitor, a cell cycle inhibitor, a cytotoxic agent, an HIV integrase inhibitor, a nucleocapsid inhibitor, and a viral entry inhibitor,
optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

16. (Original) The method according to claim 15 wherein X is an aminocyclopropyl group and R^1 and R^2 are H.

17. (Original) The method of claim 15 wherein said additional agent is a nucleoside reverse transcriptase inhibitor selected from the group consisting of AZT, 3TC, ddC, FTC, D4FC, D4T, ddI, PMPA, Bis(POC)PMPA and mixtures thereof.

18. (Currently amended) The method of claim 15 wherein said additional agent is a non-nucleoside reverse transcriptase inhibitor selected from the group consisting of Nevirapine, Delavirdine, Efavirenz, Emivirine,TIBO, ~~GW420 867X~~ GW420867X, UC 781 and mixtures thereof.

19. (Currently amended) The method of claim 15 wherein said additional agent is a protease inhibitor selected from the group consisting of Saquinavir, Amprenavir, Indinavir, Nelfinavir, Ritonavir, Tipranavir, ~~lopinavir~~ Lopinavir, GW433 908, Lasinavir and mixtures thereof.

20. (Original) The method of claim 15 wherein said additional agent is selected from the group consisting of 1,1'-azobisformamide, hydroxyurea, LiGLA, and mixtures thereof.

21. (Original) The method of claim 16 wherein said additional agent is a nucleoside reverse transcriptase inhibitor selected from the group consisting of AZT, 3TC, ddC, FTC, D4FC, D4T, ddI, PMPA, Bis(POC)PMPA and mixtures thereof.

22. (Original) The method according to claim 16 wherein said additional agent is selected from the group consisting of AZT, 3TC and mixtures thereof.

23-30 Cancelled.

Remarks

After amendment, claims 1-6, 9, and 11-23 remain pending in the present application, the claims having been amended primarily to address the Examiner's concerns regarding the prophylactic treatment of claims 7-8, 10 and 23-30. Applicants have cancelled claims 7-8, 10 and 23-30 without prejudice in order to expedite allowance of the instant application. The remaining claims have been amended to address the §112, second paragraph rejections. The amendment to the claims finds support throughout the originally filed application and claims and in particular, in the first and second full paragraphs on page 13. Both paragraphs have been amended to provide the correctly presented compound names and the claims have also been amended to reflect those minor changes. Note that the term Iopinavir has been changed to the correctly spelled term Lopinavir and GW420867X has now been more aptly labeled (by removing the spaces). No new matter has been added by the present amendment.

The Examiner has rejected or objected to the specification or claims 1-30 variously under 35 U.S.C. §112, first and second paragraphs. No prior art rejection has been made in the current office action. Applicants have amended the claims in the present application in order to obviate the Examiner's rejections. Applicants shall address each of the Examiner's objections/rejections in the sections which follow.